Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Turnaround Brewing?
The legal ghosts of the past are still rattling their chains, but 3M's operational engine is humming again. The stock clawed its way from $142.50 to $153.13 during May, delivering a dose of industrial resilience that has become rare in a market obsessed with pure AI plays.
🔹 The company is leaner and sharply refocused after the strategic separation of its healthcare unit, Solventum. 3M now trades as a pure-play industrial powerhouse, concentrating on the advanced materials, safety equipment, and manufacturing consumables that form the backbone of global infrastructure. This clarity of purpose is quietly attracting value investors who see through the legal noise.
🔹 The earnings power is real and currently undervalued. The company is generating earnings per share of $5.18, supported by operational efficiency gains and a more disciplined cost structure. The P/E ratio of 29.54 suggests the market is cautiously pricing in a recovery, not pricing in peak performance. The dividend yield of 2.04% provides a steady income stream while investors wait for the legal overhang to clear.
🔹 The PFAS challenge in Australia is significant, but it is a known quantity—a measurable liability, not an unquantifiable risk. The market often overreacts to headlines while underappreciating balance sheet fortification. 3M has been aggressively provisioning for these liabilities, and the focus is shifting from the size of the problem to the pace of resolution. Institutional analysts have placed a "Hold" rating on the stock, signaling that the downside is largely factored in and the upside depends on legal clarity.
🔹 The chart is painting a quiet base. The recovery from $142.50 shows buyers stepping in at support, and a sustained move above the $155 level would signal that accumulation is outpacing legal fear. The 200-day moving average sits as the next major test, and a break above it would attract momentum capital that has so far ignored the industrial sector.
An industrial titan trading at a discount, paying a dividend, and methodically clearing its legal decks. The headlines scream risk, but the balance sheet whispers recovery. Are you the kind of investor who buys when the fog is still thick, or do you wait for the skies to fully clear?
#TradFi交易分享挑战 $MMM
⚠️ Not financial advice.
$971 Chip. $47 Cure.
The chasm between legacy and innovation has never been wider on American exchanges. As May 2026 closes, we are witnessing a brutal divergence: artificial intelligence infrastructure is minting trillion-dollar monarchs, while biotech pioneers scrape the bargain bin. The market is ruthlessly voting for the picks-and-shovels of the A.I. gold rush, and the story is told in the cold, hard prices of these five giants.
🔹 $MU — The Memory Monarch Takes the Crown
Micron crossed the $1 trillion market cap threshold for the first time this week, a historic moment that has analysts scrambling to catch up. The stock is now at $971.00 after smashing earnings estimates by over 40%. The secret? The entire 2026 supply of high-bandwidth memory is sold out. Analysts at MarketWise are now whispering about a $2,500 long-term target, arguing that this is no longer a cyclical stock but a structural A.I. utility.
🔹 #TSM — The Geopolitical Tollbooth
Taiwan Semiconductor sits at $418.45, up a staggering 117% year-over-year and hugging its all-time highs. Owning 72% of the global foundry market, TSMC just raised 3nm prices by 15% and cranked its CapEx to the top of its $56 billion range. You can't build A.I. without chips, and you can't build cutting-edge chips without TSMC. That is not a narrative; it is a geographical monopoly.
🔹 $JNJ — The Quiet Fortress
At $225.46, Johnson & Johnson is doing what defensive giants do: surviving. With a 2.18% dividend yield and a 12% year-to-date rise, it is the adult in the room. While facing the Stelara patent cliff, the MedTech and oncology pipelines are plugging the holes, making this a favorite for those seeking shelter from the tech sector's manic swings.
🔹 $MMM — The Legal Anchor
3M is stuck in the mud at $153.13, weighed down by the PFAS "forever chemicals" legacy in Australia. Despite operational improvements, the stock is down from its February high of $173. Analysts call it a "Hold" with an average target of $172.20, but until the legal fog clears, this is a yield play handcuffed by the past.
🔹 $MRNA — The Pipeline Roulette
Moderna has collapsed to $47.23, a painful fall for the pandemic darling. The COVID cash cow is gone, and the pivot to cancer vaccines and RSV combinations is an expensive bet. The short-term charts are weak. The long-term fate rests entirely on FDA clinical results. This is a high-risk biotech lottery ticket at a deep discount.
The gulf between A.I. hardware and struggling biotech is the defining feature of this market. Micron sells shovels; Moderna searches for miracles. Right now, the crowd is sprinting toward the hardware that builds the future while cautiously watching the science that heals it.
How are you positioning in this extreme divergence—doubling down on the A.I. infrastructure boom, or quietly accumulating the beaten-down innovators waiting for their clinical breakthrough?
⚠️ Not financial advice.